Zepbound (tirzepatide) is a prescription medication approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbid condition
Adams TD, Meeks H, Fraser A, Davidson LE, Holmen J, Newman M, et al
Potential for nutrient absorption issues (related to persistent GI side effects) Persistent gastrointestinal side effects of Rybelsus, especially vomiting and diarrhea, can cause nutritional deficiencies
Your doctor can provide strategies to minimise these effects and monitor whether they affect your mental health
Can I combine this with aesthetic treatments
At a 10 mg/mL concentration, one extra unit only adds 0.1 mg